Austin Health

Title
Moderate alcohol use in fatty liver disease; don't throw the cabernet out with the bathwater.
Publication Date
2019-11-29
Author(s)
Gow, Paul J
Testro, Adam G
Hey, Penelope
Sinclair, Marie
Subject
NAFLD
cardiovascular disease
fibrosis
mortality
wine
Type of document
Journal Article
OrcId
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
DOI
10.1002/hep.31049
Abstract
We congratulate Dr Aberg and colleagues for a significant contribution to the literature on the important topic of moderate alcohol use in fatty liver disease (NAFLD) (1). Approximately 30% of the population of the Western world has obesity and/or other complications of insulin resistance and the metabolic syndrome. Due to the magnitude of this problem worldwide, palatable lifestyle therapies that are affordable, available and acceptable are necessary to curtail preventable early deaths. Moderate alcohol has the potential to fill this space, although knowledge remains limited.
Link
Citation
Hepatology (Baltimore, Md.) 2019; online first: 29 November
Jornal Title
Hepatology (Baltimore, Md.)

Files:

NameSizeformatDescriptionLink